Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eisai Co. Ltd
(OP:
ESALF
)
32.77
UNCHANGED
Last Price
Updated: 12:26 PM EDT, Oct 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
32.77
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
32.77
Today's Range
32.77 - 32.77
52wk Range
30.23 - 54.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement
August 22, 2024
The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer's. Despite this, NICE stated...
Via
Benzinga
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
July 26, 2024
The European Medicines Agency's CHMP has rejected the approval of Eisai and Biogen's Alzheimer's treatment lecanemab, citing concerns over its risks. Eisai plans to appeal the decision and work towards...
Via
Benzinga
Performance
YTD
-33.97%
-33.97%
1 Month
-13.76%
-13.76%
3 Month
-2.90%
-2.90%
6 Month
-26.64%
-26.64%
1 Year
-37.83%
-37.83%
More News
Read More
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
July 15, 2024
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
July 03, 2024
Via
Benzinga
Exposures
Product Safety
Current Analysis: Eisai Co Ltd (ESAIY)
July 16, 2023
Via
Talk Markets
Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
June 11, 2024
Via
Benzinga
Exposures
Product Safety
European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
March 22, 2024
Via
Benzinga
Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer
December 08, 2023
Via
Benzinga
Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage
October 13, 2023
Via
Benzinga
LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly
October 10, 2023
Via
Benzinga
Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories
September 25, 2023
Via
Benzinga
Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi
September 25, 2023
Via
Benzinga
Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer
September 22, 2023
Via
Benzinga
Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial
August 25, 2023
Via
Benzinga
Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts
July 07, 2023
Via
Benzinga
Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources
June 13, 2023
Via
Benzinga
Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote
June 12, 2023
Via
Benzinga
Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'
June 08, 2023
Via
Benzinga
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval
June 08, 2023
Via
Benzinga
Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen
May 04, 2023
Via
Benzinga
Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!
April 21, 2023
Via
Benzinga
Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer
April 10, 2023
Via
Benzinga
National Institute on Aging Aims Building $300M Alzheimer's Research Database
April 03, 2023
Via
Benzinga
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
March 31, 2023
Via
Benzinga
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
March 16, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
